Zogenix, Inc. (ZGNX)’s director Cam Garner Unloaded 218 shares of the Company; Profile of 14 Analysts Covering Celanese (CE)

May 18, 2018 - By Nellie Frank

Celanese Corporation (NYSE:CE) Logo

Celanese Corporation (NYSE:CE) Ratings Coverage

Among 19 analysts covering Celanese (NYSE:CE), 14 have Buy rating, 1 Sell and 4 Hold. Therefore 74% are positive. Celanese had 79 analyst reports since September 1, 2015 according to SRatingsIntel. Nomura maintained Celanese Corporation (NYSE:CE) on Wednesday, October 19 with “Neutral” rating. The stock of Celanese Corporation (NYSE:CE) has “Buy” rating given on Thursday, June 29 by Jefferies. RBC Capital Markets maintained it with “Buy” rating and $10800 target in Monday, June 19 report. The rating was maintained by KeyBanc Capital Markets with “Buy” on Thursday, August 24. The company was upgraded on Monday, January 11 by SunTrust. RBC Capital Markets maintained it with “Buy” rating and $109.0 target in Tuesday, September 5 report. The firm has “Sell” rating given on Monday, July 24 by Alembic. The stock has “Neutral” rating by UBS on Tuesday, October 17. The rating was maintained by KeyBanc Capital Markets on Wednesday, April 18 with “Buy”. Nomura maintained the stock with “Neutral” rating in Tuesday, October 10 report. See Celanese Corporation (NYSE:CE) latest ratings:

17/05/2018 Broker: UBS Old Rating: Neutral New Rating: Buy Old Target: $113 Upgrade
20/04/2018 Broker: Barclays Capital Rating: Buy New Target: $140.0000
18/04/2018 Broker: KeyBanc Capital Markets Rating: Buy New Target: $141.0000 Maintain
18/04/2018 Broker: Robert W. Baird Rating: Buy New Target: $130.0000 Maintain
17/04/2018 Broker: RBC Capital Markets Rating: Buy New Target: $128.0000 Maintain
18/04/2018 Broker: BMO Capital Markets Old Rating: Outperform New Rating: Outperform Old Target: $131 New Target: $137 Maintain
18/04/2018 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $88 New Target: $112 Maintain
27/03/2018 Broker: BMO Capital Markets Rating: Buy New Target: $131.0000 Initiate
21/03/2018 Broker: KeyBanc Capital Markets Old Rating: Overweight New Rating: Overweight Old Target: $128 New Target: $131 Maintain
20/03/2018 Broker: Robert W. Baird Rating: Buy New Target: $130.0 Maintain

Investors sentiment increased to 1.05 in 2017 Q4. Its up 0.14, from 0.91 in 2017Q3. It increased, as 29 investors sold Celanese Corporation shares while 142 reduced holdings. 54 funds opened positions while 126 raised stakes. 125.13 million shares or 1.30% less from 126.78 million shares in 2017Q3 were reported. Atlantic Tru Grp Ltd Limited Liability Company has 0% invested in Celanese Corporation (NYSE:CE). Campbell Comm Inv Adviser Limited Liability Corp invested in 0.18% or 2,295 shares. Winfield Assocs reported 60 shares stake. Gulf Retail Bank (Uk) Ltd stated it has 0.06% of its portfolio in Celanese Corporation (NYSE:CE). The California-based Los Angeles Capital Mgmt And Equity Rech Incorporated has invested 0.07% in Celanese Corporation (NYSE:CE). 37,000 were reported by Impax Asset Mgmt Lc. Profund Advsr reported 12,152 shares. Marble Harbor Inv Counsel Limited Liability Company holds 5,700 shares. Benjamin F Edwards & Incorporated has 0.02% invested in Celanese Corporation (NYSE:CE). Smith Graham & Communications Advisors Ltd Partnership invested in 0.65% or 64,550 shares. Envestnet Asset Management Inc reported 22,579 shares. Moreover, Auxier Asset has 0.62% invested in Celanese Corporation (NYSE:CE) for 30,325 shares. Amf Pensionsforsakring Ab invested in 0.39% or 369,465 shares. Northern reported 833,395 shares stake. Tcw Grp Inc reported 28,984 shares stake.

The stock increased 2.51% or $2.79 during the last trading session, reaching $113.9. About 1.92M shares traded or 116.09% up from the average. Celanese Corporation (NYSE:CE) has risen 9.78% since May 18, 2017 and is uptrending. It has underperformed by 1.77% the S&P500.

Celanese Corporation, a technology and specialty materials company, makes and sells value-added chemicals, thermoplastic polymers, and other chemical products worldwide. The company has market cap of $15.47 billion. The companyÂ’s Advanced Engineered Materials segment develops, produces, and supplies specialty polymers for automotive and medical applications, as well as for use in industrial products and consumer electronics. It has a 18.68 P/E ratio. The Company’s Consumer Specialties segment provides cellulose acetate flakes, films, and tows for use in filter products applications; food protection ingredients, such as potassium sorbate and sorbic acid for food and beverage industry; Sunett, a sweetener for use in various beverages, confections, and dairy products; and Qorus, a sweetener system designed for low-to no-calorie carbonated and non-carbonated beverages, flavored waters, energy drinks, and milk and dairy products.

More news for Celanese Corporation (NYSE:CE) were recently published by: Seekingalpha.com, which released: “Celanese weakness presents buying opportunity, Goldman analyst says” on May 01, 2018. 247Wallst.com‘s article titled: “Top Analyst Upgrades and Downgrades: AIG, Baxter, Cisco, Eiger Bio, Energy Transfer, Juniper, NOV, Phillips 66 …” and published on May 17, 2018 is yet another important article.

Zogenix, Inc., a pharmaceutical company, develops and commercializes therapies for the treatment of central nervous system disorders in the United States. The company has market cap of $1.41 billion. The companyÂ’s lead product candidate is the ZX008, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome. It currently has negative earnings. It also develops Relday, an injectable formulation of risperidone to treat the symptoms of schizophrenia and bipolar disorder in adults and teenagers with 13 years of age and older.

More notable recent Zogenix, Inc. (NASDAQ:ZGNX) news were published by: Globenewswire.com which released: “Zogenix Provides Corporate Update and Reports First Quarter Financial Results” on May 09, 2018, also Nasdaq.com with their article: “Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)” published on May 01, 2018, Nasdaq.com published: “Zogenix to Release First Quarter 2018 Financial Results and Host Conference Call and Webcast on May 9” on May 04, 2018. More interesting news about Zogenix, Inc. (NASDAQ:ZGNX) were released by: Nasdaq.com and their article: “Report: Exploring Fundamental Drivers Behind Urban Edge Properties, FLIR, Zogenix, Watts Water Technologies ..” published on April 25, 2018 as well as Nasdaq.com‘s news article titled: “Zogenix Announces Initial Quality of Life and Cognitive Function Data From Phase 3 Trial of ZX008 in Dravet Syndrome” with publication date: April 27, 2018.

Among 7 analysts covering Zogenix (NASDAQ:ZGNX), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Zogenix has $56.0 highest and $22 lowest target. $36.75’s average target is -8.01% below currents $39.95 stock price. Zogenix had 16 analyst reports since August 6, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Thursday, September 21 by Stifel Nicolaus. Leerink Swann maintained the shares of ZGNX in report on Friday, February 23 with “Outperform” rating. The firm has “Buy” rating by Stifel Nicolaus given on Monday, June 26. The stock has “Buy” rating by William Blair on Friday, September 29. The rating was maintained by Stifel Nicolaus with “Buy” on Friday, September 29. Zacks upgraded Zogenix, Inc. (NASDAQ:ZGNX) rating on Saturday, August 15. Zacks has “Hold” rating and $22 target. The firm earned “Buy” rating on Monday, November 27 by JMP Securities. The firm has “Sell” rating given on Thursday, August 6 by Zacks. The firm has “Outperform” rating by Leerink Swann given on Monday, October 2. The rating was maintained by Brean Capital with “Buy” on Friday, August 14.

Analysts await Zogenix, Inc. (NASDAQ:ZGNX) to report earnings on August, 14. They expect $-0.90 EPS, 0.00% or $0.00 from last year’s $-0.9 per share. After $-0.87 actual EPS reported by Zogenix, Inc. for the previous quarter, Wall Street now forecasts 3.45% negative EPS growth.

Celanese Corporation (NYSE:CE) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: